Question 1

What is PMC-001?

Accepted Answer

PMC-001 is a Other.

Question 2

How often does PMC-001 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was PMC-001 first tracked by Ergen?

Accepted Answer

First tracked on Jun 10, 2026.

Question 4

When was PMC-001 last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is PMC-001's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is PMC-001 in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving PMC-001?

Accepted Answer

PhoreMost announces PMC-001 for brain cancer (Jun 10, 2026, 6 articles).

Question 8

How did the "PhoreMost announces PMC-001 for brain cancer" event impact PMC-001?

Accepted Answer

PMC-001 is PhoreMost's lead oncology program, a small molecule microtubule targeting agent for brain cancers. Its development towards clinical trials represents a major advancement in cancer treatment, potentially creating a multibillion-dollar market opportunity.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.